Barclays analyst Matt Miksic raised the firm’s price target on Globus Medical (GMED) to $123 from $118 and keeps an Overweight rating on the shares following the Q4 report. The analyst says Globus remains one of the firm’s highest conviction Overweight-rated names.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: